Literature DB >> 19844240

In vivo validation of reconstruction-based resolution recovery for human brain studies.

Jurgen E M Mourik1, Mark Lubberink, Floris H P van Velden, Reina W Kloet, Bart N M van Berckel, Adriaan A Lammertsma, Ronald Boellaard.   

Abstract

The aim of this study was to validate in vivo the accuracy of a reconstruction-based partial volume correction (PVC), which takes into account the point spread function of the imaging system. The NEMA NU2 Image Quality phantom and five healthy volunteers (using [(11)C]flumazenil) were scanned on both HR+ and high-resolution research tomograph (HRRT) scanners. HR+ data were reconstructed using normalization and attenuation-weighted ordered subsets expectation maximization (NAW-OSEM) and a PVC algorithm (PVC-NAW-OSEM). HRRT data were reconstructed using 3D ordinary Poisson OSEM (OP-OSEM) and a PVC algorithm (PVC-OP-OSEM). For clinical studies, parametric volume of distribution (V(T)) images were generated. For phantom data, good recovery was found for both OP-OSEM (0.84 to 0.97) and PVC-OP-OSEM (0.91 to 0.98) HRRT reconstructions. In addition, for the HR+, good recovery was found for PVC-NAW-OSEM (0.84 to 0.94), corresponding well with OP-OSEM. Finally, for clinical data, good correspondence was found between PVC-NAW-OSEM and OP-OSEM-derived V(T) values (slope: 1.02+/-0.08). This study showed that HR+ image resolution using PVC-NAW-OSEM was comparable to that of the HRRT scanner. As the HRRT has a higher intrinsic resolution, this agreement validates reconstruction-based PVC as a means of improving the spatial resolution of the HR+ scanner and thereby improving the quantitative accuracy of positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844240      PMCID: PMC2949117          DOI: 10.1038/jcbfm.2009.225

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  27 in total

1.  Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET.

Authors:  R Boellaard; A van Lingen; S C van Balen; B G Hoving; A A Lammertsma
Journal:  Eur J Nucl Med       Date:  2001-01

2.  Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling.

Authors:  R Boellaard; A van Lingen; A A Lammertsma
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

3.  Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C]flumazenil.

Authors:  Jurgen E M Mourik; Mark Lubberink; Ursula M H Klumpers; Emile F Comans; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Neuroimage       Date:  2007-11-28       Impact factor: 6.556

4.  MR susceptibility misregistration correction.

Authors:  T S Sumanaweera; G H Glover; T O Binford; J R Adler
Journal:  IEEE Trans Med Imaging       Date:  1993       Impact factor: 10.048

5.  Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies.

Authors:  Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Carla F M Molthoff; Hugo W A M de Jong; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Phys Med Biol       Date:  2007-12-13       Impact factor: 3.609

6.  Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT.

Authors:  Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-13       Impact factor: 9.236

7.  HRRT versus HR+ human brain PET studies: an interscanner test-retest study.

Authors:  Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Fred L Buijs; Gert Luurtsema; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

8.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Authors:  Nelleke Tolboom; Maqsood Yaqub; Ronald Boellaard; Gert Luurtsema; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

9.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

10.  Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects.

Authors:  Elina Salmi; Sargo Aalto; Jussi Hirvonen; Jaakko W Långsjö; Anu T Maksimow; Vesa Oikonen; Liisa Metsähonkala; Jussi Virkkala; Kjell Någren; Harry Scheinin
Journal:  Neuroimage       Date:  2008-03-04       Impact factor: 6.556

View more
  11 in total

1.  On the assessment of spatial resolution of PET systems with iterative image reconstruction.

Authors:  Kuang Gong; Simon R Cherry; Jinyi Qi
Journal:  Phys Med Biol       Date:  2016-02-11       Impact factor: 3.609

2.  Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography.

Authors:  Kati Alakurtti; Sargo Aalto; Jarkko J Johansson; Kjell Någren; Terhi Tuokkola; Vesa Oikonen; Matti Laine; Juha O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2010-05-05       Impact factor: 6.200

3.  Comparison of HRRT and HR+ scanners for quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil brain studies.

Authors:  Floris H P van Velden; Syahir M Mansor; Daniëlle M E van Assema; Bart N M van Berckel; Femke E Froklage; Shaonan Wang; Robert C Schuit; Marie-Claude Asselin; Adriaan A Lammertsma; Ronald Boellaard; Marc C Huisman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

4.  LOCALLY WEIGHTED TOTAL VARIATION DENOISING FOR RINGING ARTIFACT SUPPRESSION IN PET RECONSTRUCTION USING PSF MODELING.

Authors:  Arthur Mikhno; Elsa D Angelini; Bing Bai; Andrew F Laine
Journal:  Proc IEEE Int Symp Biomed Imaging       Date:  2013-12-31

5.  The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition.

Authors:  K Herholz; R Evans; J Anton-Rodriguez; R Hinz; J C Matthews
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-08       Impact factor: 9.236

6.  No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.

Authors:  Daniëlle M E van Assema; Jeroen D C Goos; Wiesje M van der Flier; Mark Lubberink; Ronald Boellaard; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-16       Impact factor: 6.200

7.  P-glycoprotein function at the blood-brain barrier: effects of age and gender.

Authors:  Daniëlle M E van Assema; Mark Lubberink; Ronald Boellaard; Robert C Schuit; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

8.  Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28.

Authors:  Paolo Zanotti-Fregonara; Jeih-San Liow; Masahiro Fujita; Elodie Dusch; Sami S Zoghbi; Elise Luong; Ronald Boellaard; Victor W Pike; Claude Comtat; Robert B Innis
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

9.  Reproducibility of quantitative (R)-[11C]verapamil studies.

Authors:  Daniëlle Me van Assema; Mark Lubberink; Ronald Boellaard; Robert C Schuit; Albert D Windhorst; Philip Scheltens; Bart Nm van Berckel; Adriaan A Lammertsma
Journal:  EJNMMI Res       Date:  2012-01-17       Impact factor: 3.138

10.  Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising.

Authors:  Sandeep S V Golla; Mark Lubberink; Bart N M van Berckel; Adriaan A Lammertsma; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2017-04-21       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.